Press Release | Frontier Medicines

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets

October 21, 2025/in 2025, Featured, Press Release/by David Anderson

October 22, 2025

Frontier Medicines Announces Third Precision Oncology Development Candidate

October 15, 2025/in 2025, Press Release/by eallison

October 14, 2025

Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation

October 6, 2025/in 2025, Press Release/by eallison

October 3, 2025

Frontier Medicines to Participate in September Investor Conferences

September 1, 2025/in 2025, Press Release/by eallison

August 28, 2025

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025

August 27, 2025/in 2025, Press Release/by eallison

April 28, 2025

Frontier Medicines to Participate in Two Upcoming March Investor Conferences

August 27, 2025/in 2025, Press Release/by eallison

February 27, 2025

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

August 27, 2025/in 2025, Press Release/by eallison

January 9, 2025

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

August 27, 2025/in 2025, Press Release/by eallison

January 8, 2025

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

August 27, 2025/in 2024, Press Release/by eallison

July 23, 2024

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

August 27, 2025/in 2024, Press Release/by eallison

June 25, 2024

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets

Frontier Medicines Announces Third Precision Oncology Development Candidate

Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation

Frontier Medicines to Participate in September Investor Conferences

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025

Frontier Medicines to Participate in Two Upcoming March Investor Conferences

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

Our Locations

South San Francisco Office

Boston Office